Wang Li, Zhai Tian-Yuan, Huang Yue-E, Yao Mei-Mei, Gao Mei, Li He-Cheng, Zhao Ge-Ge
Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710000, China .
Zhonghua Nan Ke Xue. 2022 Jan;28(1):43-47.
To investigate the clinical effect of biofeedback and electrical stimulation therapy (BFES) combined with Sabale capsules (SC) on chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS).
A total of 140 outpatients meeting CP/CPPS diagnostic and research criteria in the Second Affiliated Hospital of Xi'an Jiaotong University were randomly divided into groups A (blank control), B (BFES intervention), C (SC intervention) and D (BFES+SC intervention), 35 cases in each group. The patients in group A were left untreated, while those in groups B, C and D received BFES, SC and BFES+SC, respectively, all for 12 weeks. Then the patients were followed up at 30 days after treatment and the urinary flow rate and NIH-CPSI scores were obtained and compared with the baseline.
In comparison with the baseline, the total NIH-CPSI scores after intervention were significantly decreased in groups B, ([27.30 ± 2.44] vs [19.43 ± 2.33]), C ([26.77 ± 2.54] vs [19.40 ± 2.75]) and D ([27.67 ± 3.69] vs [15.57 ± 1.94]) (all P < 0.05), and so were the individual item scores in pain or discomfort ([12.50 ± 1.94] vs [9.40 ± 2.01], [11.93 ± 1.64] vs [9.23 ± 1.96], and [12.33 ± 2.20] vs [7.50 ± 1.55]), urination symptoms ([6.07 ± 1.57] vs [3.83 ± 1.05], [5.97 ± 1.33] vs [3.77 ± 1.14], and [6.20 ± 1.88] vs [2.87 ± 0.94]), quality of life (QOL) ([8.73 ± 1.62] vs [6.20 ± 1.42], [8.87 ± 1.25] vs [6.40 ± 1.59], and [9.13 ± 1.70] vs [5.20 ± 1.40]) (all P < 0.05), while the maximum urinary flow rate (Qmax) was remarkably increased ([15.72 ± 2.38] vs [19.73 ± 2.85], [16.20 ± 2.44] vs [19.46 ± 2.48], and [15.83 ± 2.52] vs [22.49 ± 2.76]) (all P < 0.05), and so was the average urinary flow rate (Qavg) ([9. 282 ± 1.52] vs [11.27 ± 1.95], [8.97 ± 1.25] vs [11.16 ± 1.74], and [9.20 ± 1.36] vs [13.50 ± 2.30]) (all P < 0.05). The decrease in NIH-CPSI total and item scores and increase in Qmax and Qavg after treatment were more significant in group D than in B and C (P < 0.05), but showed no statistically significant difference between groups B and C (P > 0.05). Nor was any significant change observed in the above parameters in group A after treatment ( P > 0.05).
Biofeedback and electrical stimulation therapy combined with Sabale capsules can alleviate urination dysfunction, pelvic floor tension myalgia and other symptoms and significantly improve the QOL of CP/CPPS patients.
探讨生物反馈及电刺激疗法(BFES)联合沙巴棕胶囊(SC)治疗慢性前列腺炎/慢性盆腔疼痛综合征(CP/CPPS)的临床疗效。
选取西安交通大学第二附属医院符合CP/CPPS诊断及研究标准的门诊患者140例,随机分为A组(空白对照)、B组(BFES干预)、C组(SC干预)和D组(BFES+SC干预),每组35例。A组患者不做处理,B、C、D组患者分别接受BFES、SC、BFES+SC治疗,疗程均为12周。治疗结束后30天对患者进行随访,测定尿流率及NIH-CPSI评分,并与基线值比较。
与基线值比较,B组([27.30±2.44]vs[19.43±2.33])、C组([26.77±2.54]vs[19.40±2.75])和D组([27.67±3.69]vs[15.57±1.94])干预后NIH-CPSI总分均显著降低(均P<0.05),疼痛或不适单项评分([12.50±1.94]vs[9.40±2.01]、[11.93±1.64]vs[9.23±1.96]、[12.33±2.20]vs[7.50±1.55])、排尿症状评分([6.07±1.57]vs[3.83±1.05]、[5.97±1.33]vs[3.77±1.14]、[6.20±1.88]vs[2.87±0.94])、生活质量(QOL)评分([8.73±1.62]vs[6.20±1.42]、[8.87±1.25]vs[6.40±1.59]、[9.13±1.70]vs[5.20±1.40])均显著降低(均P<0.05),最大尿流率(Qmax)显著升高([15.72±2.85]vs[19.73±2.85]、[16.20±2.44]vs[19.46±2.48]、[15.83±2.52]vs[22.49±2.76])(均P<0.05),平均尿流率(Qavg)也显著升高([9.282±1.52]vs[11.27±1.95]、[8.97±1.25]vs[11.16±1.74]、[9.20±1.36]vs[13.50±2.30])(均P<0.05)。治疗后D组NIH-CPSI总分及各单项评分的降低幅度和Qmax、Qavg的升高幅度均大于B组和C组(P<0.05),B组和C组比较差异无统计学意义(P>0.05)。治疗后A组上述指标均无明显变化(P>0.05)。
生物反馈及电刺激疗法联合沙巴棕胶囊可缓解CP/CPPS患者排尿功能障碍、盆底紧张性肌痛等症状,显著提高患者生活质量。